BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 24628463)

  • 1. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
    Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
    Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
    Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
    Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
    Song MK; Chung JS; Lee JJ; Lee JH; Song IC; Lee SM; Shin DY; Lee GW; Lee IS
    Acta Haematol; 2015; 134(1):7-16. PubMed ID: 25832367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
    Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Raab MS; Hillengass M; Wagner B; Jauch A; Hose D; Weber MA; Delorme S; Goldschmidt H; Hillengass J
    Haematologica; 2015 Jun; 100(6):818-25. PubMed ID: 25795721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.
    Lecouvet FE; Vande Berg BC; Michaux L; Malghem J; Maldague BE; Jamart J; Ferrant A; Michaux JL
    Radiology; 1998 Dec; 209(3):653-60. PubMed ID: 9844655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
    Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
    Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
    Lee SE; Yoon JH; Shin SH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK
    Ann Hematol; 2014 Apr; 93(4):627-34. PubMed ID: 24085241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.